Genta Stops Active Marketing Of Ganite
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta stops actively marketing its cancer-related hypercalcemia treatment Ganite as part of company restructuring
|
Genta stops actively marketing its cancer-related hypercalcemia treatment Ganite as part of company restructuring. In order to direct more resources to the development of the metastatic melanoma therapy Genasense (oblimersen), currently under review at FDA, Genta is reducing its workforce by 45% or 85 employees, including sales reps. On May 3, FDA's Oncologic Drugs Advisory Committee voted 12 to 4 that Genta's pivotal trial for Genansense did not show a "real effect" on progression-free survival (1 (Also see "Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says" - Pink Sheet, 3 May, 2004.)). |